Pacira BioSciences announced the upcoming presentation of new data in support of its gene therapy candidate, PCRX-201. The data will be presented at the American College of Rheumatology’s annual ACR Convergence meeting, being held in Washington, D.C. November 14-19. Presentation Title: Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the KneePCRX-201 is a locally administered gene therapy, designed to produce interleukin-1 receptor antagonist, a naturally occurring, anti-inflammatory protein with a proven mechanism of action that reduces interleukin-1 signaling, a known factor in the development and progression of osteoarthritis of the knee. Unlike systemically administered gene therapies, PCRX-201 delivers the medicine where it matters and uses an inducible promoter to mimic the body’s natural response to inflammation by “turning on” the expression of IL-1Ra when inflammation is present in the joint to reduce pain and disability and potentially slow structural progression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- DOMA Perpetual urges Pacira to accelerate, increase its stock repurchases
- Pacira price target raised to $18 from $15 at Jefferies
- Largest borrow rate increases among liquid names
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Warner Bros. downgraded, Starbucks upgraded: Wall Street’s top analyst calls